Biotech RadarJobs updated

COMPANY

Attovia Therapeutics

HQ: San Carlos, CA source · attovia.com ↗ · West Coast

Clinical Phase 2

3 open jobs · last seen Oct 23, 2026 · 5 sources

Keywords: immunology dermatology gastroenterology Atopic Dermatitis Atopic Eczema Chronic Pruritus of Unknown Origin Ulcerative Colitis Atopic Eczema/Dermatitis (Non-Specific) Chronic Pruritus ATTO-1310 ATTO-1091 ATTO-3712

Profile checked Oct 10, 2026

3Open jobs$90.0MRaised (2 yrs)4Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, Strategic InsightsSan Carlos, CASep 25, 2026Oct 11, 2026
Director, CMC ManagementSan Carlos, CASep 3, 2026Oct 11, 2026
Head of IRSan Carlos, CAAug 23, 2026Oct 11, 2026

See all 3 jobs

Timeline

  1. Trial start Phase 2: Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin source ↗
  2. Trial start Phase 1: Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis source ↗
  3. Trial start Phase 1: Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis source ↗
  4. Raise Private equity round — Series C: $90M (total, as published), announced Apr 15, 2025. Source: company release on GlobeNewswire. source ↗
  5. Trial start Phase 1: Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $90.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07833306Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown OriginPhase 2Not yet recruitingDec 21, 2026Aug 30, 2028 (estimated)
NCT07819799Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative ColitisPhase 1Not yet recruitingDec 14, 2026Jul 15, 2028 (estimated)
NCT07205081Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic DermatitisPhase 1CompletedOct 22, 2025Aug 13, 2026 (actual)
NCT06787586Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic PruritusPhase 1CompletedJan 14, 2025Jun 11, 2026 (actual)

Open jobs 3

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, Strategic InsightsSan Carlos, CASep 25, 2026Oct 11, 2026Senior
Director, CMC ManagementSan Carlos, CASep 3, 2026Oct 11, 2026Senior
Head of IRSan Carlos, CAAug 23, 2026Oct 11, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Attovia Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback